2025 2(49) 16

Actuarial activities in life insurance and critical illness insurance (including health insurance): features of the theory and practice of genetic discrimination

Arych M.,
Candidate of Economics, Associate Professor, 
ORCID https://orcid.org/0000-0002-0910-2332
e-mail: mykhailo.arych@gmail.com
National University of Food Technologies, Kyiv,
2025/2026 Fellow of the Virtual Ukraine Institute for Advanced Study (VUIAS)

Citation Format
Arych, M. (2025). Actuarial activities in life insurance and critical illness insurance (including health in-surance): features of the theory and practice of genetic discrimination. Vіsnyk ekonomіchnoі nauky Ukraіny, 2 (49), 144-151. https://doi.org/10.37405/1729-7206.2025.2(49).144-151

Language
 Ukrainian

Resume
This article provides an in-depth examination of prevailing trends in the conceptual and applied dimensions of genetic discrimination within actuarial practices governing life insurance and critical illness insurance, including health insurance. Particular emphasis is placed on the expanding role of genetic information in underwriting procedures and actuarial risk stratification.
The study systematizes categories of diseases for which genetic data concerning the probability of disease manifestation are most frequently utilized by insurance undertakings in the evaluation of insurance risks. It is convincingly argued that the valid and methodologically sound interpretation of genetic information necessitates a holistic assessment of the insurance applicant’s overall health profile, incorporating clinical, environmental, and behavioral determinants. The article demonstrates that the fragmented or erroneous interpretation of genetic data may result in distorted actuarial estimations, institutionalized forms of genetic discrimination, and economically unjustified adjustments in insurance premiums.
Empirical cases of genetic discrimination arising in actuarial activities within the domains of life and health insurance are subjected to systematic analysis. The findings reveal that the most recurrent manifestations of genetic discrimination in insurance markets encompass: (1) outright denial of insurance coverage or the imposition of actuarially inflated premiums, particularly in relation to African Americans carrying the sickle cell anemia gene; (2) adverse modification of contractual conditions or refusal to insure individuals exhibiting a genetic predisposition to Huntington’s disease; and (3) exclusion from coverage under health insurance policies for individuals possessing gene mutations associated with an elevated risk of developing Long QT syndrome.
The article further substantiates a set of regulatory and financial mechanisms aimed at mitigating genetic discrimination in insurance practice. These mechanisms include the application of individualized premium-setting models, the establishment of segregated insurance risk pools, and the partial subsidization of life insurance costs through public budgetary instruments.

Keywords
life insurance, critical illness insurance, health insurance, actuarial activity, genetic discrimination, genetic information, insurance risk.

Referensces

  1. Arych, M. (2025). Сonceptual approaches to the interpretation and meaning of genetic information for insurance risk assessment. Svit finansiv, 3(84), 109-122. https://doi.org/10.35774/sf2025.03.109 [in Ukrainian].
  2. Arych, M., & Joly, Y. (2022). Genetic Discrimination in Access to Life Insurance: Does Ukrainian Legislation Offer Sufficient Protection against the Adverse Consequences of the Genetic Revolution to Insurance Applicants? Laws, 11(1), 2. https://doi.org/10.3390/laws11010002
  3. Barlow-Stewart, K., Taylor, S. D., Treloar, S. A., Stranger, M., & Otlowski, M. (2009). Verification of consumers’ experiences and perceptions of genetic discrimination and its impact on utilization of genetic testing. Genetics in medicine, 11(3), 193–201. https://doi.org/10.1097/GIM.0b013e318194ee75
  4. Bombard, Y., & Lemmens, T. (2010). Insurance and Genetic Information. In Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. https://doi.org/10.1002/9780470015902.a0005203.pub3
  5. Dixon, P., Horton, R. H., Newman, W. G., McDermott, J. H., & Lucassen, A. (2024). Genomics and insuran­ce in the United Kingdom: increasing complexity and emerging challenges. Health economics, policy, and law, 19(4), 446–458. https://doi.org/10.1017/S1744133124000070
  6. Godard, , Raeburn, S., Bobrow, M., Farndon, P., Ayme, S. (2003). Genetic information and testing in insurance and employment: Technical, social and ethical issues. European Journal of Human Genetics, 11(2), 123-142. https://doi.org/10.1038/sj.ejhg.5201117
  7. Howard, C.W. (2014). Genetic Testing Model: If Underwriters Had No Access to Known Results. Report to CIA Research Committee. Document 214082.
  8. Hudson, K. L., Rothenberg, K. H., Andrews, L. B., Kahn, M. J., & Collins, F. S. (1995). Genetic discrimi­nation and health insurance: an urgent need for reform. Science, 270(5235), 391–393. https://doi.org/10.1126/270.5235.391 
  9. Joly, Y., Ngueng Feze, I., & Simard, J. (2013). Genetic discrimination and life insurance: a systematic review of the evidence. BMC medicine, 11, 25. https://doi.org/10.1186/1741-7015-11-25
  10. Joly, Y., Huerne, K., Arych, M., Bombard, Y., De Paor, A., Dove, E. S., Granados Moreno, P., Ho, C., Ho, C. H., Van Hoyweghen, I., Kim, H., Lebret, A., Minssen, T., Ó Cathaoir, K., Prince, A., Nair, A., Otlowski, M., Pepper, M. S., Sladek, R., Song, L., Voigt, T. H. , Zawati, M. H., & Dalpe, G. (2021). Genetic Discrimination Observatory. The Genetic Discrimination Observatory: confronting novel issues in genetic discrimination. Trends in genetics: TIG, 37(11), 951–954.
  11. Joly, Y., Dalpe, G. (2022). Genetic discrimination still casts a large shadow in 2022. European Journal of Human Genetics, 30, 1320–1322. https://doi.org/10.1038/s41431-022-01194-8
  12. Karlsson Linner, R., & Koellinger, P. D. (2021). Genetic risk scores in life insurance underwriting. Journal of health economics, 81, 102556. https://doi.org/10.1016/j.jhealeco.2021.102556
  13. Keogh, L. A., & Otlowski, M. F. (2013). Life insurance and genetic test results: a mutation carrier’s fight to achieve full cover. The Medical journal of Australia, 199(5), 363–366. https://doi.org/10.5694/mja13.10202
  14. Lacaze, P., Ryan, J., Woods, R., Winship, I., & McNeil, J. (2017). Pathogenic variants in the healthy elderly: unique ethical and practical challenges. Journal of medical ethics, 43(10), 714–722. https://doi.org/10.1136/medethics-2016-103967
  15. Macdonald, А. (2011). The Actuarial Relevance of Genetic Information in the Life and Health Insurance Context. Office of the Privacy Commissioner of Canada.
  16. Macdonald, A. S., & Yu, F. (2011). The impact of genetic information on the insurance industry: conclusions from the ‘bottom-up’ modelling programme. ASTIN Bulletin: The Journal of the IAA, 41(2), 343-376. https://doi.org/10.2143/AST.41.2.2136981
  17. Macdonald, A. S. (1999). Modeling the impact of genetics on insurance. North American Actuarial Journal, 3, 83–105. https://doi.org/10.1080/10920277.1999.10595777
  18. National Library of Medicine (n.d.). Genetic Testing Registry. Retrieved October 23, 2025, from https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=all%5Bsb%5D&
  19. Oleksyk, T.K., Wolfsberger, W.W., Weber, A., Shchubelka, K., Oleksyk, O., Levchuk, O. & oth. (2021). Genome diversity in Ukraine, GigaScience, 10(1): giaa159. https://doi.org/10.1093/gigascience/giaa159
  20. Otlowski, M., Barlow-Stewart, K., Taylor, S., Stranger, M., & Treloar, S. (2007). Investigating genetic discrimination in the Australian life insurance sector: the use of genetic test results in underwriting, 1999-2003. Journal of law and medicine, 14(3), 367–396.
  21. Prince, A. E. R., Suter, S. M., Uhlmann, W. R., & Scherer, A. M. (2022). The goldilocks conundrum: Disclosing discrimination risks in informed consent. Journal of genetic counseling, 31(6), 1383–1393. https://doi.org/10.1002/jgc4.1613
  22. Rechfeld, F. (2024). Genetic testing in the Life & Health insurance industry. Swiss Re Management Ltd. https://www.swissre.com/institute/research/topics-and-risk-dialogues/health-and-longevity/genetic-testing-in-life-health-insurance-industry.html (дата звернення: 05.09.2025).
  23. Tiller, J., Otlowski, M., & Lacaze, P. (2017). Should Australia Ban the Use of Genetic Test Results in Life Insurance?. Frontiers in public health, 5, 330. https://doi.org/10.3389/fpubh.2017.00330
  24. Tiller, J., Bakshi, A., Dowling, G., Keogh, L., McInerney-Leo, A., Barlow-Stewart, K., Boughtwood, T., Gleeson, P., Delatycki, M. B., Winship, I., Otlowski, M., & Lacaze, P. (2024). Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing. European journal of human genetics, 32(3), 286–294. https://doi.org/10.1038/s41431-023-01373-1
  25. Vukcevic, D., & Chen, J. (2018). Advances in genetics and their impact on life insurance. In Proceedings of Financial Services Forum 2018 Institute of Actuaries of Australia. https://research.monash.edu/en/publications/advances-in-genetics-and-their-impact-on-life-insurance
  26. World Health Organization (2025). International Statistical Classification of Diseases and Related Health Problems (ICD). https://www.who.int/standards/classifications/classification-of-diseases

Full Text (.pdf)

Received: 27.11.2025
Accepted: 19.12.2025
Published: 29.12.2025